Effect of long-term oral testosterone undecanoate treatment on prostate volume and serum prostate-specific antigen concentration in eugonadal middle-aged men.
Testosterone undecanoate (160 mg/day) or placebo was given orally in a double-blind fashion for 8 months to 23 middle-aged men without urinary tract symptoms. Testosterone was found to increase the mean prostate volume by 12% (P < .012). The treatment suppressed the serum concentrations of sex-hormone-binding globulin and follicle stimulating hormone. The observed decrease in the mean serum concentration of luteinizing hormone was not statistically significant. The serum concentrations of prostate-specific antigen did not change as measured by two different well-validated immunometric assays. No changes in micturition habits or urine flow charts were reported.
Holmäng
S
S
Department of Urology, Sahlgrenska Sjukhuset, University of Göteborg, Sweden.
Mårin
P
P
Lindstedt
G
G
Hedelin
H
H
D000284:Administration, Oral; D000328:Adult; D004311:Double-Blind Method; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D008297:Male; D008875:Middle Aged; D011467:Prostate / Q000187:drug effects*; D017430:Prostate-Specific Antigen / Q000097:blood*; D012738:Sex Hormone-Binding Globulin / Q000032:analysis; D013739:Testosterone / Q000031:analogs & derivatives* / Q000494:pharmacology
D012738:Sex Hormone-Binding Globulin; D013739:Testosterone; D005640:Follicle Stimulating Hormone; D017430:Prostate-Specific Antigen; C010792:testosterone undecanoate